Skip to main content

GORE® ENFORM Biomaterial Product Study

Recruiting · Not applicable · NCT04718168

Conditions: Hernia, Ventral, Hernia, Hiatal, Hernia, Diaphragmatic, Incisional Hernia

At a glance

Research payments reported, 2025
$127,477
U.S. investigators named
6
Sites paid
7
Planned or actual enrollment
245

About the trial

Sponsor
W.L.Gore & Associates
Tested
Gore ENFORM Biomaterial (Preperitoneal) (device), Gore ENFORM Biomaterial (Intraperitoneal) (device)
Dates
Started 2021-05-17; completion 2026-12
Results posted
Not yet

A prospective, retrospective, non-randomized, multicenter study with two independent hernia study cohorts (Ventral / Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair). The primary objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on device functional performance and short-term patient experience.

From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

W. L. Gore & Associates, Inc. reported $127,477 in research payments for this study in 2025 (16 payments).

Products named: Gore Enform Preperitoneal Biomaterial, Product in Development

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.